Loopbaan van Tamara Byk
Eerdere bekende functies van Tamara Byk
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| EVOGENE LTD. | Hoofd Techniek/Wetenschap/O&O | 01-08-2006 | 01-10-2009 |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 01-01-2002 | 01-01-2004 |
| SOLEGREEN | Corporate Officer/Principal | - | - |
Opleiding van Tamara Byk
| The Hebrew University of Jerusalem | Doctorate Degree |
Statistieken
Internationaal
| Israël | 4 |
| Verenigde Staten | 2 |
Operationeel
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
| Utilities | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| EVOGENE LTD. | Health Technology |
| SOLEGREEN | Utilities |
| Bedrijven in privébezit | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Beurs
- Insiders
- Tamara Byk
- Ervaring
